Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.47 USD
Change Today +0.12 / 5.11%
Volume 236.6K
NYMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

nymox pharmaceutical corp (NYMX) Snapshot

Open
$2.30
Previous Close
$2.35
Day High
$2.47
Day Low
$2.30
52 Week High
10/7/14 - $5.55
52 Week Low
12/12/14 - $0.33
Market Cap
86.6M
Average Volume 10 Days
311.1K
EPS TTM
$-0.62
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NYMOX PHARMACEUTICAL CORP (NYMX)

nymox pharmaceutical corp (NYMX) Related Bloomberg News

View More Bloomberg News

nymox pharmaceutical corp (NYMX) Related Businessweek News

No Related Businessweek News Found

nymox pharmaceutical corp (NYMX) Details

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. It offers NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products; and AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. The company’s products under development include NX-1207 for the treatment of benign prostatic hyperplasia, localized prostate cancer, and hepatocellular carcinoma; and NXC-4720, an anti-bacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. The company markets NicAlert and TobacAlert tests through its marketing arm and distributors in North America, Europe, and Asia, as well as TobacAlert through online at tobacalert.com. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Saint Laurent, Canada.

nymox pharmaceutical corp (NYMX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

nymox pharmaceutical corp (NYMX) Key Developments

Nymox Pharmaceutical Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Nymox Pharmaceutical Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of goods of $55,824 against $97,880 a year ago. Net loss from operating activities was $23,218,796 against $776,275 a year ago. Net loss attributable to the equity holders of the corporation was $23,275,704 against $820,272 a year ago. Net loss per basic and diluted share were $0.63 against $0.02 a year ago. For the six months, the company reported sales of goods of $131,211 against $176,044 a year ago. The decrease for the quarter and the first six months of 2014 compared to the same periods in 2013 is primarily due to the non-recurrence of the sale of goods of $84,753 for the quarter ended June 30, 2013 and $157,679 for the six months period ended June 30, 2013 under its licensing agreement with Recordati. Net loss from operating activities was $21,589,758 against $3,363,485 a year ago. Net loss attributable to the equity holders of the corporation was $21,699,153 against $3,413,088 a year ago. Net loss per basic and diluted share were $0.59 against $0.10 a year ago. Cash flows used in operating activities was $1,319,219 against $2,796,285 a year ago.

Nymox Pharmaceutical Corporation Appoints James G. Robinson to the Board of Directors

On June 30, 2015 the Board of Directors of Nymox Pharmaceutical Corporation confirmed the appointment of James G. Robinson to the Board of Directors. James G. Robinson is Chairman and CEO of Morgan Creek Productions, which for over 25 years has continued to be of independent production entities in the film business.

Nymox Pharmaceutical Corporation Announces Appointment of Randall J. Lanham, Esq. as the company’s Secretary and General Counsel

The Board of Directors of Nymox Pharmaceutical Corporation confirmed the appointment of Randall J. Lanham, Esq. as the company’s Secretary and General Counsel. Mr. Lanham has been a board member for eight years and is now reappointed as a board member and an officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NYMX:US $2.47 USD +0.12

NYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.57 USD -1.72
Laboratory Corp of America Holdings $115.75 USD -2.06
OraSure Technologies Inc $5.32 USD -0.08
ProMIS Neurosciences Inc C$0.08 CAD 0.00
Quest Diagnostics Inc $65.70 USD -2.10
View Industry Companies
 

Industry Analysis

NYMX

Industry Average

Valuation NYMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NYMOX PHARMACEUTICAL CORP, please visit www.nymox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.